Bio-Rad Laboratories, Inc. (BIO) vs Cellectis S.A. (CLLS)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| BIO | CLLS | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Biotechnology |
| Size band | MID | SMALL |
| Listing | NYSE | Nasdaq GM |
| Country | United States | France |
| Theme | life-science-tools | cell-therapy |
| Price and returns | ||
| Last close | $372.43 | $0.97 |
| Return · 1 week | +5.56% | +4.37% |
| Return · 1 month | −1.39% | −34.70% |
| Return · 3 months | +12.52% | −65.97% |
| Return · year to date | +22.00% | −79.86% |
| Return · 1 year | +10.80% | −73.37% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −6.01% | −82.27% |
| 52-week high | $396.23 | $5.45 |
| 52-week low | $236.73 | $0.88 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $9.97B | $97.36M |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $93.82M | $39.87K |
| Employees | 7,450 | 224 |
| Valuation | ||
| Price to earnings · trailing | 46.41× | n/a (negative earnings) |
| Price to earnings · forward | 36.92× | n/a (negative forward earnings) |
| Price to sales | 3.78× | 1.99× |
| Price to book | 1.36× | 2.23× |
| Enterprise value to EBITDA | 21.75× | n/a (negative EBITDA) |
| Enterprise value to revenue | 3.70× | 0.17× |
| PEG ratio | 4.01 | — |
| Earnings per share · trailing | 7.89 | -0.64 |
| Profitability | ||
| Gross margin | 51.90% | 82.27% |
| Operating margin | 11.18% | −340.69% |
| Profit margin | 8.59% | −102.34% |
| Return on equity | 3.11% | −94.54% |
| Return on assets | 1.66% | −11.67% |
| Growth | ||
| Revenue growth | −0.10% | −62.10% |
| Earnings growth | +18.70% | — |
| Balance sheet and payout | ||
| Debt / equity (%) | 19.10 | 195.66 |
| Current ratio | 3.14 | 1.37 |
| Dividend yield | 0.00% | 0.00% |
| Payout ratio | 0.00% | 0.00% |
| Trend and volatility | ||
| RSI · 14 | 54.82 | 23.09 |
| ADX · 14 | 17.76 | 58.26 |
| 50-day average | $373.32 | $2.05 |
| 200-day average | $312.23 | $3.13 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 3.00% | 9.62% |
The full BIO analysis
Everything this table leaves out for Bio-Rad Laboratories, Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the BIO argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full BIO analysisThe full CLLS analysis
Everything this table leaves out for Cellectis S.A.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the CLLS argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full CLLS analysis